1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   Response - Informed Consent Form
   Response - Clinical Study Report
   Response -  Analytic Code
   
   
3. Who will be able to view these files?
   Response - Anyone
   


4. For what types of analyses will this data be available?
   Response - For individual participant data meta-analysis.
   


5. By what mechanism will data be made available?
   Response - Proposals should be directed to [tejashree.darshu@gmail.com].
   


6. For how long will this data be available start date provided 05-07-2025 and end date provided 01-07-2026?
   Response - Immediately following publication. No end date.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

Oral sub mucous fibrosis (OSMF) is a chronic, premalignant condition of the oral mucosa its insidious, chronic disease affecting any part of the oral cavity and sometimes the pharynx. OSMF is also characterized by reduced movement and depapillation of the tongue, blanching and leathery texture of the oral mucosa, progressive reduction of mouth opening, and shrunken uvula. Dysphonia and hearing impairment is also observed in advanced cases . Quality of life (QoL) is severely affected, worsening with increasing stage of the disease.  The malignant transformation rate of OSMF has been reported to be in the range of 7–13%, studies with smaller follow up periods report malignant transformation rates ranging from 1.9–9%. 

Conventional medical management includes avoidance of irritating substance like betel chewing, tobacco ingestion or smoking etc. and involves regular administration of corticosteroids, either via submucosal injections or topical application . Steroids suppress or prevent inflammatory reactions, also act as immunosuppressive agents. They can prevent fibrosis by decreasing deposition of collagen and fibroblastic proliferation. Steroids such as dexamethasone, triamcinolone, betamethasone, and hydrocortisone have been used in the treatment of OSMF. 

Recently platelet rich plasma (PRP) treatment is gaining popularity in oral

and dental surgery. Platelet rich plasma acts by inducing the platelets to secrete proinflammatory mediators and growth factors. These, in turn, initiate the cascade of wound healing and bring about tissue remodeling. 

This study is designed to evaluate the effect of Dexamethasone versus platelet rich plasma in improving trismus due to oral submucous fibrosis.